Progress in targeted therapy for triple-negative breast cancer / 中华内分泌外科杂志

ABSTRACT

Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, accounting for about 15%-20% of all breast cancer patients. Its characteristics such as young age of onset, high risk of recurrence and visceral metastasis, and poor prognosis make it an urgent problem to be solved in clinical practice. With the rapid progress of genomics and proteomics, more and more potential therapeutic targets of TNBC have been identified, and the preliminary results show that these targets are promising to transform the treatment mode of TNBC in the future. This article reviews the clinical trials and applications of TNBC targeted drugs, as well as gives a brief introduction to nanomedicine.